Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Rives

Hand Surgery Santa Barbara, CA Medical Doctor

NPI 1508084690 CMS profile 113798

2323 De La Vina St Ste 201, Santa Barbara, CA 93105

Open in the dashboard

General payments

$993

26 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$299,996

3 holdings reported · through program year 2025

Through program year 2025, Adam Rives of Santa Barbara, CA is reported in the CMS Open Payments database as having received $993 across 26 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $299,996 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Hand Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $141 5
2024 General $91 3
2023 General $342 5
2022 General $12 1
2021 General $72 2
2020 General $30 2
2019 General $306 8
2025 Ownership $99,998 1
2024 Ownership $99,998 1
2023 Ownership $100,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Rives
  • Hand Surgery median
  • Middle half of Hand Surgery
  • National median

In program year 2025, general payments to Adam Rives were reported at $141. Among 1,842 Hand Surgery profiles paid that year, the median was $270 and the middle half received between $102 and $1,118.

Show as a table
Year Adam Rives Hand Surgery median Middle half National median
2019 $306 $383 $106–$1,905 $163
2020 $30 $172 $51–$1,268 $114
2021 $72 $263 $71–$1,591 $132
2022 $12 $336 $87–$1,938 $149
2023 $342 $233 $81–$1,114 $160
2024 $91 $258 $88–$1,203 $164
2025 $141 $270 $102–$1,118 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TriMed, Inc. $289 3 payments
  2. AxoGen $127 2 payments
  3. Stryker Corporation $119 3 payments
  4. Bioventus LLC $109 4 payments
  5. Alafair Biosciences,Inc. $108 1 payment
  6. Endo Pharmaceuticals Inc. $80 5 payments
  7. Pacira Pharmaceuticals Incorporated $60 1 payment
  8. Electronic Waveform Lab, Inc. $40 4 payments
  9. DePuy Synthes Sales Inc. $39 2 payments
  10. Endo USA, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $806 24 payments
  2. Education $127 1 payment
  3. Honoraria $60 1 payment
Products named General payments · program years 2019–2025
  1. AxoGuard Nerve Connector $127 2 payments
  2. AXOGUARD NERVE PROTECTOR $127 2 payments
  3. VARIAX $119 3 payments
  4. VersaWrap $108 1 payment
  5. XIAFLEX $101 6 payments
  6. EXOGEN ULTRASOUND BONE HEALING SYSTEM $80 3 payments
  7. Exparel $60 1 payment
  8. Tools - AFS $50 1 payment
  9. VA-LCP $39 2 payments
  10. Supartz Fx Sodium Hyaluronate $30 1 payment
  11. Other $62 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 119 billing codes

Paid by Medicare

$256,041

Of which drugs: $2,891

Medicare patients

443

Average age 74

Services billed

2,975

267 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 62%
High blood pressure 58%
Depression 23%
Osteoporosis 20%
Diabetes 18%
Ischemic heart disease 17%
Chronic kidney disease 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 122 521 $2,887
Injection, lidocaine hcl for intravenous infusion, 10 mg J2001 Office 11 11 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hand Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record